Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Domenico Russo

Showing results (271-280 of 305) with videos related to

Pageof 31
Sort By:
The EMBO Journal|March 22, 2021
Golgi maturation-dependent glycoenzyme recycling controls glycosphingolipid biosynthesis and cell growth via GOLPH3Riccardo Rizzo, Domenico Russo, Kazuo Kurokawa, et al.
Transplantation and Cellular Therapy|January 27, 2025
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE StudyFederico Stella, Martina Pennisi, Annalisa Chiappella, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Diderik-Jan Eikema, Linda Koster, et al.
Hematological Oncology|April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patientsNicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Frontiers in Bioengineering and Biotechnology|July 30, 2024
Hydrogel-chitosan and polylactic acid-polycaprolactone bioengineered scaffolds for reconstruction of mandibular defects: a preclinical <i>in vivo</i> study with assessment of translationally relevant aspectsMarco Ferrari, Stefano Taboni, Harley H L Chan, et al.
The New England Journal of Medicine|January 7, 2016
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host DiseaseNicolaus Kröger, Carlos Solano, Christine Wolschke, et al.
Blood Cancer Journal|August 21, 2024
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trialGianluca Cavallaro, Anna Grassi, Chiara Pavoni, et al.
The Lancet. Haematology|September 23, 2024
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trialDomenico Russo, Nicola Polverelli, Simona Bernardi, et al.
The Lancet. Haematology|February 3, 2019
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised studyFrancesca Bonifazi, Carlos Solano, Christine Wolschke, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Pageof 31

Showing results (271-280 of 305) with videos related to

Sort By:
Pageof 31
The EMBO Journal|March 22, 2021
Golgi maturation-dependent glycoenzyme recycling controls glycosphingolipid biosynthesis and cell growth via GOLPH3Riccardo Rizzo, Domenico Russo, Kazuo Kurokawa, et al.
Transplantation and Cellular Therapy|January 27, 2025
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE StudyFederico Stella, Martina Pennisi, Annalisa Chiappella, et al.
Bone Marrow Transplantation|January 10, 2024
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTMitja Nabergoj, Diderik-Jan Eikema, Linda Koster, et al.
Hematological Oncology|April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patientsNicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Frontiers in Bioengineering and Biotechnology|July 30, 2024
Hydrogel-chitosan and polylactic acid-polycaprolactone bioengineered scaffolds for reconstruction of mandibular defects: a preclinical <i>in vivo</i> study with assessment of translationally relevant aspectsMarco Ferrari, Stefano Taboni, Harley H L Chan, et al.
The New England Journal of Medicine|January 7, 2016
Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host DiseaseNicolaus Kröger, Carlos Solano, Christine Wolschke, et al.
Blood Cancer Journal|August 21, 2024
Busulfan-fludarabine versus busulfan-cyclophosphamide for allogeneic transplant in acute myeloid leukemia: long term analysis of GITMO AML-R2 trialGianluca Cavallaro, Anna Grassi, Chiara Pavoni, et al.
The Lancet. Haematology|September 23, 2024
Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trialDomenico Russo, Nicola Polverelli, Simona Bernardi, et al.
The Lancet. Haematology|February 3, 2019
Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised studyFrancesca Bonifazi, Carlos Solano, Christine Wolschke, et al.
Haematologica|January 29, 2026
GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trialFriedrich Stölzel, Matthias Stelljes, Dietrich Wilhelm Beelen, et al.
Pageof 31